Geode Capital Management’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-19,285
| Closed | -$10.2K | – | 4583 |
|
|
2025
Q1 | $10.2K | Buy |
19,285
+7,209
| +60% | +$11.9K | ﹤0.01% | 4429 |
|
|
2024
Q4 | $63.5K | Sell |
12,076
-464
| -4% | -$3.05K | ﹤0.01% | 4198 |
|
|
2024
Q3 | $180K | Buy |
12,540
+1,001
| +9% | +$13.7K | ﹤0.01% | 3938 |
|
|
2024
Q2 | $187K | Buy |
11,539
+2,415
| +26% | +$60.6K | ﹤0.01% | 3932 |
|
|
2024
Q1 | $924K | Buy |
9,124
+1,422
| +18% | +$89.9K | ﹤0.01% | 3394 |
|
|
2023
Q4 | $182K | Hold |
7,702
| – | – | ﹤0.01% | 3980 |
|
|
2023
Q3 | $159K | Buy |
7,702
+858
| +13% | +$16.6K | ﹤0.01% | 4071 |
|
|
2023
Q2 | $178K | Hold |
6,844
| – | – | ﹤0.01% | 4095 |
|
|
2023
Q1 | $142K | Hold |
6,844
| – | – | ﹤0.01% | 4198 |
|
|
2022
Q4 | $139K | Sell |
6,844
-16
| -0.2% | -$301 | ﹤0.01% | 4268 |
|
|
2022
Q3 | $189K | Hold |
6,860
| – | – | ﹤0.01% | 4247 |
|
|
2022
Q2 | $181K | Sell |
6,860
-6,611
| -49% | -$294K | ﹤0.01% | 4334 |
|
|
2022
Q1 | $1.08M | Buy |
13,471
+1,198
| +10% | +$148K | ﹤0.01% | 3586 |
|
|
2021
Q4 | $2.5M | Buy |
12,273
+1,383
| +13% | +$345K | ﹤0.01% | 3270 |
|
|
2021
Q3 | $3.52M | Buy |
10,890
+3,351
| +44% | +$978K | ﹤0.01% | 3115 |
|
|
2021
Q2 | $1.96M | Buy |
7,539
+2,841
| +60% | +$866K | ﹤0.01% | 3273 |
|
|
2021
Q1 | $1.81M | Buy |
+4,698
| New | +$1.9M | ﹤0.01% | 3295 |
|
Other funds holding VINC
Geode Capital Management's VINC Position: Q2 2025 in Review
Geode Capital Management sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2025, closing a stake of 19,285 shares — an estimated $10.2K sold.
Geode Capital Management first reported a position in VINC in Q1 2021 and held it in 17 quarters. The position peaked at $3.52M in Q3 2021. 1 fund tracked by Wall St. Rank holds VINC as of Q2 2025.
- Geode Capital Management reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Geode Capital Management sold 19,285 Vincerx Pharma, Inc. Common Stock shares in Q2 2025, an estimated $10.2K.
- Geode Capital Management first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 17 quarters.
- Geode Capital Management's Vincerx Pharma, Inc. Common Stock position peaked at $3.52M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2025.
Based on Geode Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.